Navigation Links
Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
Date:9/19/2013

esponding compounds to the pharmaceutical industry. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. These statements include, but are not limited to, Omeros' expectations regarding subsequent Phase 2 and 3 clinical trials; the timing of completion of the current trial; the potential therapeutic benefits of OMS824; the potential qualities of OMS824; and that it may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Reports Additional Positive Results from OMS824 Program
2. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
3. Omeros to Present at the Stifel Healthcare Conference 2013
4. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
5. Omeros Corporation Reports Second Quarter 2013 Financial Results
6. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
7. Omeros Submits New Drug Application to U.S. FDA for OMS302
8. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
9. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
10. Omeros Corporation Reports First Quarter 2013 Financial Results
11. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011 Varian Medical Systems (NYSE: VAR ... information system has received Surescripts® e-prescribing certification for new ... ARIA system to manage radiation therapy treatments will be ... the Surescripts network. "E-Prescribing allows the ...
... Mont., May 5, 2011 Bacterin International Holdings, ... a creator and developer of revolutionary bone graft material ... it is commencing distribution of the Company,s third human ... Bacterin,s hMatrix® is an acellular matrix processed ...
Cached Medicine Technology:The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 2The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 3Bacterin International Holdings Launches Third Biologic Scaffold 2Bacterin International Holdings Launches Third Biologic Scaffold 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... other particles tracked indoors can be harmful, researchers warn , ... that coats your furniture and floors comes from outdoors and ... The researchers developed a computer model that can track the ... found that more than 60 percent of household dust originates ...
... ... featured Keynote at this year,s Molecular Medicine Tri-Conference, is the inspiration for a new ... ... 11, 2009 -- Cambridge Healthtech Institute,s (CHI) flagship event, the Molecular Medicine Tri-Conference (February ...
... WellPoint,s affiliated Life and Disability Companies are pleased to announce ... help new mothers adjust to their newborn baby and return ... available to all new and in-force short term disability plans ... have access to Newborn and Parenting Resources once their baby ...
... Internationally recognised refractive ... talk the audience through each step of the procedure as the laser treatment is being ... ... procedure in a free live broadcast. He will talk the audience through each step of ...
... ... ... HEALTHeCAREERS , North America’s premier healthcare Network, is advertising more than 14,000 job ... to be one of the few bright spots in the North American job market. ...
... Vivacare.com ... honor of Epilepsy Awareness Month. , ... Berkeley, CA (PRWEB) Nov 9, 2009 -- Vivacare provides ... in honor of Epilepsy Awareness Month. , , , , ,Leading neurologists, such as ...
Cached Medicine News:Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:WellPoint's Affiliated Life and Disability Companies Offer Newborn and Parenting Resources to Ease New Mothers' Transition Back to Work After Maternity Leave 2Health News:Eye Surgeon Broadcasts own Surgery 2Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Neurologists Receive New Patient Education Resources from Vivacare for Epilepsy Awareness Month 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
... Conserver., ,Offers an average 5:1 increase in ... the use of a standard cannula. , ... cylinders offers ambulatory oxygen patients a superior alternative ... a 2-year warranty. , ...
Medicine Products: